Mirati and Novartis Pair Up to Evaluate Drug Combinations to Target KRAS G12C Mutations

San Diego-based Mirati Therapeutics and Swiss pharma giant Novartis have teamed up to evaluate the combination of an investigational KRAS G12C inhibitor and an investigational SHP2 inhibitor in patients with advanced solid tumors that harbor KRAS G12C mutations.